Pre-made Cemiplimab benchmark antibody ( Whole mAb, anti-PDCD1 therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-097
Anti-PDCD1 therapeutic antibody (Pre-made Cemiplimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Cemiplimab, sold under the brand name Libtayo, is a monoclonal antibody medication for the treatment of squamous cell skin cancer. Cemiplimab belongs to a class of drugs that binds to the programmed death receptor-1 (PD-1), blocking the PD-1/PD-L1 pathway.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-PDCD1 therapeutic antibody (Pre-made Cemiplimab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Inovio Pharmaceuticals;ISA Pharmaceuticals;Regeneron Pharmaceuticals;Sanofi;Sidney Kimmel Cancer Center;SillaJen Biotherapeutics;University of Texas M. D. Anderson Cancer Center|
|Conditions Approved||Squamous cell cancer;Basal cell cancer;Non-small cell lung cancer|
|Conditions Active||Cervical cancer;Oropharyngeal cancer;Prostate cancer;Fallopian tube cancer;Glioblastoma;Multiple myeloma;Ovarian cancer;Peritoneal cancer;Solid tumours;Head and neck cancer;Malignant melanoma;Renal cell carcinoma|
|Conditions Discontinued||B-cell lymphoma|